Statistics

Total Visits

Views
Phase II Trial of Erlotinib plus Capecitabine as First-line Treatment for Metastatic Pancreatic Cancer (XELTA Study)14

Select a period of time:

Number of views in the range

Views
Phase II Trial of Erlotinib plus Capecitabine as First-line Treatment for Metastatic Pancreatic Cancer (XELTA Study)7

Views

Views
May 20244
June 20240
July 20242
August 20240
September 20241
October 20240
November 20240
Download CSV file
 untranslated
 untranslated

Top country views

Views
United States6
United Kingdom1
 

Top cities views

Views
Chicago3
Fort Worth1